Dr. Martina RossiPhDGHK-Cu is an endogenous copper-binding tripeptide — glycyl-L-histidyl-L-lysine bound to copper(II) — studied most heavily for its effects on collagen synthesis and extracellular matrix biology relevant to tissue repair, with a newer strand of preclinical research now examining how it behaves in the nervous system. The peptide occurs naturally in human plasma, saliva, and urine, and its plasma concentration has been reported to decline with age. All published research on GHK-Cu is preclinical, drawn from cell-culture and animal models, and no approved human clinical trials have validated these effects.
GHK-Cu research sits at an unusual intersection of skin biology, metal chemistry, and, more recently, neuroscience. This article summarizes what preclinical research has investigated about GHK-Cu: its identity as an endogenous tripeptide, its documented effects on collagen and extracellular matrix biology, and emerging 2024 data on copper handling and neuroprotection. It is written for researchers and informed readers, and it describes what studies have investigated rather than any outcome an individual should expect. GHK-Cu is a research compound and is not characterized for human use here.
GHK is the tripeptide glycyl-L-histidyl-L-lysine, a naturally occurring sequence found in human plasma, saliva, and urine. Its defining chemical feature is a high affinity for copper(II) ions, which it binds to form the complex written as GHK-Cu. As reviewed by Pickart and Margolina, the free peptide was first identified in human plasma and its concentration declines with age, falling substantially between early adulthood and later life, a change that has motivated much of the interest in it as a marker of tissue maintenance capacity.[1] The same review summarizes gene-expression data indicating that GHK-Cu influences the activity of a broad set of human genes linked to tissue remodeling, antioxidant defense, and repair, which frames the molecule less as a single-target drug and more as a copper-delivery and signaling peptide. This gene-level breadth is the backdrop for the more specific connective-tissue and nervous-system findings that follow.
The most established body of GHK-Cu research concerns the extracellular matrix, the scaffold of collagen, elastin, and glycosaminoglycans that gives connective tissue its structure. The evidence separates usefully into in vitro cell-culture work and in vivo animal studies.
Maquart and colleagues showed that GHK-Cu stimulated collagen synthesis in cultured fibroblasts, an early and direct cellular link between the peptide and matrix production.[2] Work from the same research line extended this to other matrix components, with Wegrowski and colleagues reporting that GHK-Cu stimulated the synthesis of sulfated glycosaminoglycans in culture, indicating that its influence reaches beyond collagen to the wider matrix.[3] These are cell-culture findings and describe what the peptide did to cells in a dish, not a predicted result in an organism.
Animal work then tested whether these cellular effects appeared in living tissue. In a rat wound-chamber model, Maquart and colleagues found that GHK-Cu produced a concentration-dependent increase in connective tissue accumulation, with rises in total protein, collagen, DNA, and glycosaminoglycan content, and an increase in type I and type III collagen messenger RNA.[4] In that study a control tripeptide had no such effect, and the collagen-related messenger RNA rose without a parallel rise in TGF-beta messenger RNA, which helped characterize the response as relatively specific. A later rat study by Siméon and colleagues examined the same wound setting and reported that GHK-Cu modulated the expression of glycosaminoglycans and small proteoglycans during healing.[5] Taken together, the in vitro and animal matrix data are the most internally consistent part of the GHK-Cu literature.
The newer and less settled strand of GHK-Cu research asks whether the peptide's copper handling matters in the nervous system, where both copper and zinc can drive protein misfolding. In a 2024 in vitro study, Min and colleagues demonstrated that GHK bound copper and reduced its redox activity, prevented copper- and zinc-induced protein aggregation, and protected central nervous system cells from copper- and zinc-induced death in culture.[6] The same work reported that GHK could resolubilize an already aggregated model protein and could attenuate the increased copper toxicity seen under inflammatory conditions. These are cell-culture results, and the authors framed them as a rationale for further investigation rather than as evidence of a treatment effect.
A separate 2024 study by Tucker and colleagues moved the question into an animal model, reporting reduced pathology markers and improved behavioral measures in a transgenic mouse strain, which the authors described as a rationale for additional studies.[7] It aligns directionally with earlier review-level discussion by Pickart and colleagues, who proposed, on the basis of the peptide's antioxidant and gene-modulating properties, that GHK-Cu was worth examining in the context of aging.[8] The nervous-system picture is therefore early: one in vitro mechanism paper and one animal model study, supported by a conceptual review.
Several limitations shape how this literature should be read. The connective-tissue evidence, while consistent, comes substantially from a small number of affiliated research groups, which makes independent replication important. The nervous-system strand is genuinely new, resting on a single in vitro study and a single small animal study, and no conclusion about human outcomes can be drawn from either. Copper itself is a double-edged element, useful in trace amounts and harmful in excess, so the framing of GHK-Cu as copper-delivering versus copper-buffering may depend heavily on tissue and context. Finally, the breadth of gene-level effects reported for the peptide, while striking, complicates any simple mechanistic account.
GHK-Cu is best understood as an endogenous copper-binding tripeptide whose plasma level declines with age and whose most established research concerns collagen and extracellular matrix biology, documented in both cultured cells and rodent wound models. A newer line of preclinical work, centered on 2024 studies, has begun to examine its copper handling in the nervous system, with in vitro protection against copper- and zinc-driven protein aggregation and an animal model reporting reduced pathology markers. GHK-Cu research peptide is intended for laboratory research use only, and the findings above describe what has been investigated, not what any individual should expect.
GHK-Cu (Copper Peptide) is available for laboratory research from Pure Peptides. View Product →
References
WRITTEN BY
Dr. Martina Rossi
PhD — Scientific Contributor and Reviewer
Dr. Martina Rossi holds a PhD from Universite Grenoble Alpes, where her doctoral research examined the vascular functions of Bone Morphogenetic Proteins in knockout mouse models. Her published work spans cell and molecular biology, vascular biology, and gene therapy, with peer-reviewed contributions appearing in journals including Cardiovascular Research, Scientific Reports, and Brain Sciences. Dr. Rossi serves as Scientific Contributor and Reviewer for the Pure Peptides research content program, independently reviewing articles for scientific accuracy.
View team profile →
An evidence-led look at BPC-157 research into tissue repair, covering proposed angiogenic mechanisms, tendon and ligament studies in rodent models, and the current absence of human trial data.
